Last $869.88 MXN
Change Today 0.00 / 0.00%
Volume 0.0
MDT* On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 4:09 PM 09/10/14 All times are local (Market data is delayed by at least 15 minutes).

medtronic inc (MDT*) Snapshot

Open
$869.88
Previous Close
$869.88
Day High
$869.88
Day Low
$869.88
52 Week High
09/10/14 - $869.88
52 Week Low
09/19/13 - $685.35
Market Cap
852.1B
Average Volume 10 Days
113.0
EPS TTM
--
Shares Outstanding
979.5M
EX-Date
10/1/14
P/E TM
--
Dividend
$1.22
Dividend Yield
1.72%
Current Stock Chart for MEDTRONIC INC (MDT*)

medtronic inc (MDT*) Details

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

49,247 Employees
Last Reported Date: 06/20/14
Founded in 1949

medtronic inc (MDT*) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic inc (MDT*) Key Developments

Medtronic Announces First U.S. Implants in Clinical Study of Recapturable CoreValve Evolut R

Medtronic, Inc. announced the first U.S. implants in the CoreValve Evolut R Clinical Study, which will evaluate the safety and effectiveness of the new Medtronic CoreValve(R)Evolut(TM) R System. This novel investigational self-expanding valve and 14FR equivalent delivery system offer new capabilities that are designed to advance deliverability and valve performance while providing the option to recapture and reposition the CoreValve Evolut R valve during deployment, if needed, while performing transcatheter aortic valve replacement (TAVR). In clinical trials and real-world use, patients treated with the current CoreValve System have experienced high rates of survival, low rates of stroke and improved quality of life. This study will build on that strong legacy by evaluating the next generation of this successful system, a recapture-enabled valve with the lowest-profile delivery system. The prospective CoreValve Evolut R Clinical Study will enroll up to 250 patients with severe symptomatic aortic stenosis who are considered at high or extreme risk for open-heart surgical aortic valve replacement, at up to 25 U.S. sites. The primary endpoints are all-cause mortality and disabling stroke at 30 days, as well as device success rate at 24 hours to seven days. Secondary endpoints include recapture success rate, when attempted, and hemodynamic (blood flow) performance. The new system consists of the CoreValve Evolut R transcatheter valve and the EnVeo(TM) R Delivery System. The new valve is anatomically designed to increase conformability at the annulus for optimal annular fit and sealing, while maintaining supra-annular valve position for improved blood flow and hemodynamic performance. The EnVeo R delivery system offers a new InLine Sheath which significantly reduces the profile of the catheter shaft to 14 Fr equivalent (less than 1/5 inch). The EnVeo system's 1:1 delivery response is designed to provide first-time valve placement accuracy during deployment. The new system builds on experience from more than 65,000 CoreValve System implants worldwide.

Medtronic Kicks Irish Device Company Acquisition

Medtronic, Inc. (NYSE:MDT)'s plan to buy an Irish device company and move the merged operation's headquarters over there has kicked up a lot of controversy, not the least of which concerns Medtronic's plan to pick up millions of dollars in taxes the deal creates for Medtronic's top leaders.

Medtronic Announces CE Mark for Recapturable CoreValve Evolut R System

Medtronic, Inc. announced CE (Conformite Europeene) Mark for the 23 mm CoreValve(R) Evolut(TM) R System for transcatheter aortic valve implantation (TAVI). The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that advance valve performance and deliverability during the procedure, while providing the option to recapture (re-sheath the valve back into the catheter) and reposition (move the valve to a new position either above or below its current placement) the valve during deployment phase, if needed. The novel system consisting of the CoreValve Evolut R transcatheter aortic valve and the EnVeo(TM) R Delivery Catheter System is designed for first-time positioning accuracy and also offers a new InLine(TM) Sheath that significantly reduces the profile to the lowest on the market (14 Fr equivalent, less than 1/5 inch); a smaller profile size is believed to minimize the risk of major vascular complications. The new valve is anatomically designed to increase conformability at the annulus for optimal annular fit and sealing, while maintaining supra-annular valve position for improved hemodynamic performance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT*:MM $869.88 MXN 0.00

MDT* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.55 USD -0.01
Allergan Inc/United States $169.25 USD +0.92
Astellas Pharma Inc ¥1,594 JPY +49.50
Becton Dickinson and Co $113.71 USD -1.48
Covidien PLC $90.67 USD -0.58
View Industry Companies
 

Industry Analysis

MDT*

Industry Average

Valuation MDT* Industry Range
Price/Earnings 22.1x
Price/Sales 3.8x
Price/Book 3.3x
Price/Cash Flow 19.2x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.